Genakumab
Malignant Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 73/ 100
Competitive context
29 Active assets in the Malignant Solid Tumors cohort.
View all 38 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →